Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 6, 2024
Product Development
Clinical report: Akero’s efruxifermin shows deepening treatment effect at 96 weeks
Plus: Novo positions Ozempic to add CKD to label and updates from Apogee, RegenxBio, Ironwood
BioCentury | May 23, 2023
Deals
Sizing up VectivBio’s takeout premium among '23 M&A deals
Many companies with late-stage assets have commanded triple-digit premiums
BioCentury | Oct 14, 2022
Finance
Oct. 13 Quick Takes: Epic $168M round for Glick’s Odyssey
Plus Dice raises $300M on back of data, Liu’s Prime Medicine seeking $1.6B valuation, and updates from VectivBio, CSPC, Relmada and more
BioCentury | Oct 1, 2022
Product Development
Sept. 30 Quick Takes: Intercept NASH candidate fails Phase III, NDA resubmission on track
Plus Zealand to advance glepaglutide to NDA and updates from Valneva and YS Pharma
BioCentury | Mar 30, 2022
Finance
March 30 Quick Takes: Neuron23 taps Softbank for $100M series C
Plus Akebia dips after FDA issues CRL for vadadustat, and updates from IGM, Adagio and more
BioCentury | Dec 21, 2021
Deals
Happy customer: Sanofi buying Amunix in $1B deal
Bay Area company’s platform helps overcome toxicity issues that have dogged immuno-oncology modalities
BioCentury | Oct 16, 2020
Finance
VectivBio prepping pivotal GI trial with $110M crossover round that could presage IPO
A public listing could be VectivBio’s next financial step now that it has raised $110 million in a crossover round that will fund its planned Phase III trial in short bowel syndrome, as well as
BioCentury | Jan 7, 2020
Company News
VectivBio reunites ex-Therachon management, VCs for short bowel program
VectivBio launches with $35M, hopes to build pipeline beyond the asset it was created to house
BioCentury | May 17, 2019
Company News
May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid
BioCentury | May 8, 2019
Company News
Why dwarfism start-up Therachon picked Pfizer takeout over IPO
At the cusp of seeking a public listing, Therachon Holding chose $340M deal with Pfizer and the chance to spin out a new company
Items per page:
1 - 10 of 132